The Lung Cancer Foundation of America Clinical Trial Principal Investigator Grant Program provides two awards of $150,000 each over three years to protect research time for junior clinical investigators leading national thoracic oncology trials.
The program supports National Principal Investigators on eligible National Clinical Trials Network (NCTN) therapeutic trials. Disease areas include non-small cell lung cancer, small cell lung cancer, mesothelioma, thymoma, thymic carcinoma and pulmonary carcinoid.
Eligibility Criteria
- Hold an MD, DO or equivalent degree.
- Be an Assistant Professor with fewer than six years at that rank when the trial activates; exceptions require prior consultation.
- Be a US citizen or permanent resident.
- Serve as National PI on a fully approved NCTN Phase II/III or Phase III therapeutic trial.
- The trial must be about to activate or activate within six months.
- Eligible groups are Alliance, ECOG-ACRIN, SWOG and NRG.
- Nominations must come from an NCTN lung cancer or thoracic oncology committee chair, with Group Chair support.
- The institution must confirm support and acceptance of the award terms.
Funding Details
- Total per award: $150,000.
- Annual funding: $50,000 for three years.
- Number of awards: Two.
- Funds primarily support the National PI’s salary for protected research time.
- Institutional overhead: Not permitted.
- Reallocation to other direct costs requires prior written approval.
Deadline
- Nomination deadline: December 1, 2026.
- Award announcement: February 2027, at the IASLC Targeted Therapy Meeting.
Further Information
- Official program page
- Application guidelines
- Submission: Committee chairs email the nomination package to grants@lcfamerica.org.